MCSim-related pages

GNU MCSim page on Wikipedia

Journal of Statistical Software

Data on Statlib for Gelman, Bois, Jiang, JASA, 1996 paper

SAL-Numerical Analysis

Duke University: Institute of Statistics and Decision Sciences

University of Bristol: Neural Network Information

Pasteur Institute: Software

Molecular Monte Carlo Software

Delorie Free Software

A real conversation supported by an MCSim simulation model

Scientific works acknowledging the use of MCSim

1. Allen, B.C., Hack E.C., Clewell H.J., 2007,
   "Use of Markov chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in u.s. women of childbearing age".
   Risk Analysis, 27:947-959.
2. Banks H.T., Ma Y., Potter, L.K., 2005,
   "A Simulation-based comparison between parametric and nonparametric estimation methods in PBPK Models",
   Journal of Inverse and Ill-posed Problems, 13:1����26.
3. Bernillon P., Bois F., 2000,
   "Statistical issues in toxicokinetic modeling: A Bayesian perspective",
   Environmental Health Perspectives, 108(suppl.5):883-893.
4. Bois F., 1999,
   "Analysis of PBPK models for risk characterization."
   Annals of the New York Academy of Sciences 895: 317-337.
5. Bois F., 2000,
   "Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics."
   Environmental Health Perspectives 108 (suppl. 2): 307-316.
6. Bois F., 2000,
   "Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics."
   Environmental Health Perspectives 108 (suppl. 2): 275-282.
7. Bois F., 2001,
   "Applications of population approaches in toxicology."
   Toxicology Letters 120:385-394.
8. Bois F., 2003,
   "Toxicokinetic modelling of 2,3,7,8-tetrachloro-p-dioxin blood concentration after ingestion by women."
   Environnement, Risque et Sante 2:45-53.
9. Bois F., Fahmy T., et al., 1997,
   "Dynamic modeling of bacteria in a pilot drinking water distribution system."
   Water Research 31:3146-3156.
10. Bois F., Gelman A., et al., 1996,
    "Population toxicokinetics of tetrachloroethylene."
    Archives of Toxicology 70: 347-355.
11. Bois F., Jackson E., et al., 1996,
    "Population toxicokinetics of benzene."
    Environmental Health Perspectives 104 (suppl. 6): 1405-1411.
12. Bois F., Krowech G., et al., 1995,
    "Human interindividual variability in metabolism: the example of 4-aminobiphenyl."
    Risk Analysis 15: 205-213.
13. Bois F., Maszle D., 1997,
    MCSim: A simulation program,
    Journal of Statistical Software, 2(9):http://www.stat.ucla.edu/journals/jss/v02/i09.
14. Bois F., Paxman D., 1992,
    "An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model."
    Regulatory Toxicology and Pharmacology 15: 122-136.
15. Bois F., Smith M., et al., 1991,
    "Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism."
    Toxicology Letters 56: 283-298.
16. Bois F., Smith T., et al., 1999,
    "Optimal design for a study of butadiene toxicokinetics in humans."
    Toxicological Sciences 49: 213-224.
17. Bois F., Woodruff T.J., et al., 1991,
    "Comparison of three physiologically-based pharmacokinetic models of benzene disposition."
    Toxicology and Applied Pharmacology 110: 79-88.
18. Bois F., Zeise L., et al., 1990,
    "Precision and sensitivity analysis of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats and humans."
    Toxicology and Applied Pharmacology 102: 300-315.
19. Brochot C., Bessoud B., et al., 2006,
    "Evaluation of antiangiogenic treatment effects on tumors microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging."
    Magnetic Resonance Imaging, 24:1059-1067.
20. Brochot C., Bois F., 2005,
    "Use of a chemical probe to increase safety for human volunteers in toxicokinetic studies".
    Risk Analysis 25:1559-1571.
21. Brochot C., Marchand S., Couet W., Gelman A., Bois F., 2004,
    "Extension of the isobolographic approach to interactions studies between more than two drugs: Illustration with the convulsant interaction between pefloxacin, norfloxacin and theophylline in rats".
    Journal of Pharmaceutical Sciences, 93:553-562.
22. Brochot C., Smith T.J., Bois F., 2007,
    "Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: Global sensitivity analysis for experimental design issues".
    Chemico-Biological Interactions, 167:168-183.
23. Cancre N., Bois F., et al., 1999,
    "Screening blood donations for hepatitis C in central Africa: Analysis of a risk- and cost-based decision tree".
    Medical Decision Making, 19:296-306.
24. Cancre N., Tall A., et al., 2000,
    "Bayesian analysis of an epidemiological model of P. falciparum malaria infection in Ndiop, Senegal". American Journal of Epidemiology, 152:760-770.
25. Chiu W.A., Bois F., 2006,
    "Revisiting the population toxicokinetics of tetrachloroethylene".
    Archives of Toxicology, 80:386-386.
26. Chiu W.A., Bois F., 2007,
    "An approximate method for population toxicokinetic analysis with aggregated data".
    Journal of Agricultural, Biological, and Environmental Statistics, 12:346-363.
27. Chiu W.A., Micallef S., Monster A.C., Bois F., 2007,
    "Toxicokinetics of inhaled trichloroethylene and tetrachloroethylene in humans at 1 ppm: Empirical results and comparisons with previous studies".
    Toxicological Sciences, 95:23-36.
28. Covington T.R., Gentry P.R., et al., 2007,
    "The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene",
    Regulatory Toxicology and Pharmacology, 47:1-18.
29. David, R. M., H. J. Clewell, et al., 2006,
    "Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations."
    Regulatory Toxicology and Pharmacology 45: 55-65.
30. Diack C., Bois F., 2005,
    "Pharmacokinetic-pharmacodynamic models for categorical toxicity data,"
    Regulatory Toxicology and Pharmacology, 41:55-65.
31. Eisenberg J.N, Seto E., et al, 1996,
    "Quantifying water pathogen risk in an epidemiological framework",
    Risk Analysis, 16:549-563.
32. Franks S.J., Spendiff M.K., et al., 2006,
    "Physiologically based pharmacokinetic modelling of human exposure to 2-butoxyethanol",
    Toxicology Letters 162 (2006) 164����173.
33. Gelman A., Bois F., Jiang J., 1996,
    "Physiological pharmacokinetic analysis using population modeling and informative prior distributions,"
    Journal of the American Statistical Association, 91:1400-1412.
34. Hack E.C., 2006,
    "Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models".
    Toxicology, 221:241-248.
35. Hack E.C., Chiu W.A, et al., 2006,
    "Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites", Regulatory Toxicology and Pharmacology, 46:63-83.
36. Johanson G., Jonsson F., Bois F., 1999,
    "Development of new technique for risk assessment using physiologically based toxicokinetic models",
    American Journal of Industrial Medecine, Suppl. 1:101-103.
37. Jonsson F, Jonsson E.N., Bois F., Marshall S., 2007, The application of a Bayesian approach to the analysis of a complex, mechanistically based model, Journal of Biopharmaceutical Statistics, 17:65-92.
38. Jonsson F., Bois F., Johanson G., 2001, Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects, Archives of Toxicology, 75:189-199.
39. Jonsson F., Bois F., Johanson G., 2001, Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise, Toxicological Sciences, 59:209-218.
40. Jonsson, F. and G. Johanson, 2003,
    "The Bayesian population approach to physiological toxicokinetic-toxicodynamic models - An example using the MCSim software."
    Toxicology Letters 138: 143-150.
41. Liao K.H., Tan Y.-M., et al.,2007,
    "Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform",
    Risk Analysis, 27:1535-1551.
42. Lin H.I., Berzins D.W., et al., 2004,
    "A Bayesian approach to parameter estimation for a crayfish (procambarus spp.) bioaccumulation model".
    Environmental Toxicology and Chemistry: Vol. 23, No. 9 pp. 2259����2266.
43. Loizou G., Spendiff M., 2005,
    "A human PBPK model for ethanol describing inhibition of gastric motility",
    Journal of Molecular Histology, 35:687-696.
44. Lyons M.A., Yang R.S.H, 2008,
    "Computational toxicology of chloroform: reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomonitoring data",
    Environmental Health Perspectives, 116:1040����1046.
45. Marino, D. J., H. Clewell, et al., 2006,
    "Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice".
    Regulatory Toxicology and Pharmacology 45: 44-54.
46. Mezzetti M., Ibrahim J.G., et al., 2003,
    "A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism".
    Journal of the Royal Statistical Society, Series C, 52:291-305.
47. Micallef S., Amzal B., Bach V., Chardon K., Tourneux P., Bois F., 2007, Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates, Clinical Pharmacokinetics, 46:59-74.
48. Micallef, S., Bois F., 2004, [Application of physiological models to toxicokinetic data analysis], Journal de la Societe Fran��aise de Statistique, 145:15-32.
49. Micallef, S., Brochot, C., Bois F., 2005, [Bayesian statistical analysis of toxicokinetic data], Environnement, Risque et Sante, 4:21-34.
50. Nong, A., Y. M. Tan, et al., 2008,
    "Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition."
    Journal of Toxicology and Environmental Health - Part A - Current Issues 71(20): 1363-1381.
51. Smith T., Bois F., Lin Y.-S., Brochot C., Micallef S., Kim D., Kelsey K.T., 2008, Quantifying heterogeneity in exposure-risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures, Journal of Breath Research, 2:037018 (10 p.)
52. Smith T., Lin Y.-S., Mezzetti L., Bois F., Kelsey K., Ibrahim J., 2001, Genetic and dietary factors affecting human metabolism of 1,3-butadiene, Chemico-Biological Interactions, 135-136, special issue):407-428.
53. Spear R., Bois F., 1994, Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results, Environmental Health Perspectives, 102(suppl. 11):61-66.
54. Spear R., Bois F., et al., 1991,
    "Modeling benzene pharmacokinetics: Calibration and parametric sensitivity across three sets of animal data",
    Risk Analysis, 11:641-654.
55. Verotta D., 2005,
    "Models and estimation methods for clinical HIV-1 data",
    Journal of Computational and Applied Mathematics, 184:275-300.
56. Watanabe K., Bois F., 1996, Interspecies extrapolation of physiological pharmacokinetic parameter distributions, Risk Analysis, 16:741-754.
57. Watanabe K.H., Bois F., et al., 1994,
    "Benzene toxicokinetics in humans: Bone marrow exposure to metabolites",
    Occupational and Environmental Medicine, 51:414-420.
58. Watanabe K.H., Lin H.-I., 2005,
    "Bayesian estimation of kinetic rate constants in a food-web model of polycyclic aromatic hydrocarbon bioaccumulation",
    Ecological Modelling 181:229����246.
59. Woodruff T., Bois F., et al., 1992,
    "Structure and parametrization of toxicokinetic models: Their impact on model predictions",
    Risk Analysis, 12:189-201.
60. Woodruff T.J., Bois F., 1993,
    "Optimization issues in physiological toxicokinetic modeling: A case study with benzene",
    Toxicology Letters, 69:181-196.
61. Yokley K. Tran H.T., et al., 2006
    "Physiologically-based pharmacokinetic modeling of benzene in humans: A Bayesian approach",
    Risk analysis, 26:925-943.